Skip to main content
SpringerLink
Log in

Survival and prognostic factors after adjuvant 131iodine-labeled lipiodol for hepatocellular carcinoma: a retrospective analysis of 106 patients over 20 years

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

Hepatocellular carcinoma (HCC) has high recurrence rate after curative treatment. The aim of the present study was to report our experience with adjuvant use of 131I-lipiodol after curative treatment of HCC in terms of recurrence and survival in a large cohort of patients with a long follow-up.

Methods

All patients treated with 131I-lipiodol after curative treatment of HCC in two French centers from 1991 to 2009 were included in a retrospective cohort study.

Results

One hundred and six patients were included. The median (range) follow-up was 6 years (0.3–22). Forty-three patients (41%) had cirrhosis. Recurrence-free survival rates at 1, 2, 5, 10, and 20 years were 73, 57, 40, 30, and 14%, respectively. Cirrhosis was an independent predictive factor of recurrence [RR = 1.18, 95% CI (1.11–3.02), p = 0.019]. Overall, survival rates at 1, 2, 5, 10, and 20 years were 90, 83, 59, 37, and 23%, respectively. Prognostic factors were recurrence [RR = 2.73, 95% CI (1.35–5.54); p = 0.005], age over 60 years (RR = 1.91, 95% CI [1.02–3.61]; p = 0.044), and tumor number over 3 [RR = 3.31, 95% CI (1.25–8.77); p = 0.016].

Conclusion

Our results suggest that the effect of 131I-lipiodol after curative treatment of HCC could be related to a beneficial impact on risk factors of early tumor recurrence. This could be evaluated in further studies using modern radioembolization methods.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

    Article  PubMed  Google Scholar 

  2. Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980–2004. Hepatology. 2008;48:137–45.

    Article  PubMed  Google Scholar 

  3. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25:181–200.

    Article  PubMed  Google Scholar 

  4. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010;52:762–73.

    Article  CAS  PubMed  Google Scholar 

  5. Belghiti J, Panis Y, Farges O, Benhamou JP, Fekete F. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg. 1991;214:114–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200–7.

    Article  PubMed  Google Scholar 

  7. Samuel M, Chow PK-H, Chan Shih-Yen E, Machin D, Soo K-C. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev. 2009.

  8. European Association For The Study Of The Liver. European organisation for research and treatment of cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.

    Article  Google Scholar 

  9. Lau WY, Leung TW, Ho SK, Chan M, Machin D, Lau J, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet. 1999;353:797–801.

    Article  CAS  PubMed  Google Scholar 

  10. Lau WY, Lai ECH, Leung TWT, Yu SCH. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival. Ann Surg. 2008;247:43–8.

    Article  PubMed  Google Scholar 

  11. Partensky C, Sassolas G, Henry L, Paliard P, Maddern GJ. Intra-arterial iodine 131–labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma: a phase 2 clinical study. Arch Surg. 2000;135:1298–300.

    Article  CAS  PubMed  Google Scholar 

  12. Dumortier J, Decullier E, Hilleret M-N, Bin-Dorel S, Valette P-J, Boillot O, et al. Adjuvant intraarterial lipiodol or 131I-lipiodol after curative treatment of hepatocellular carcinoma: a prospective randomized trial. J Nucl Med. 2014;55:877–83.

    Article  CAS  PubMed  Google Scholar 

  13. Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, et al. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143:986–94.

    Article  CAS  PubMed  Google Scholar 

  14. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.

    Article  CAS  PubMed  Google Scholar 

  15. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation. Hepatology. 1999;30:1434–40.

    Article  CAS  PubMed  Google Scholar 

  16. Zhong J-H, Li H, Li L-Q, You X-M, Zhang Y, Zhao Y-N, et al. Adjuvant therapy options following curative treatment of hepatocellular carcinoma: a systematic review of randomized trials. Eur J Surg Oncol. 2012;38:286–95.

    Article  PubMed  Google Scholar 

  17. Xie F, Zhang X, Li H, Zheng T, Xu F, Shen R, et al. Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. PLoS One. 2012;7:e42879.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Zhong J-H, Ma L, Wu L-C, Zhao W, Yuan W-P, Wu F-X, et al. Adoptive immunotherapy for postoperative hepatocellular carcinoma: a systematic review. Int J Clin Pract. 2012;66:21–7.

    Article  PubMed  Google Scholar 

  19. Bruix J, Takayama T, Mazzaferro V, Chau G-Y, Yang J, Kudo M, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16:1344–54.

    Article  CAS  PubMed  Google Scholar 

  20. Yoshida H, Shiratori Y, Kudo M, Shiina S, Mizuta T, Kojiro M, et al. Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology. 2011;54:532–40.

    Article  CAS  PubMed  Google Scholar 

  21. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med. 1996;334:1561–8.

    Article  CAS  PubMed  Google Scholar 

  22. Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med. 1999;340:1046–7.

    Article  CAS  PubMed  Google Scholar 

  23. Takai K, Okuno M, Yasuda I, Matsushima-Nishiwaki R, Uematsu T, Tsurumi H, et al. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. Updated analysis of the long-term follow-up data. Intervirology. 2005;48:39–45.

    Article  CAS  PubMed  Google Scholar 

  24. Okita K, Izumi N, Matsui O, Tanaka K, Kaneko S, Moriwaki H, et al. Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. J Gastroenterol. 2014;50:191–202.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Boucher E, Bouguen G, Garin E, Guillygomarch A, Boudjema K, Raoul J-L. Adjuvant intraarterial injection of 131I-labeled Lipiodol after resection of hepatocellular carcinoma: progress report of a case-control study with a 5-year minimal follow-up. J Nucl Med. 2008;49:362–6.

    Article  PubMed  Google Scholar 

  26. Chua TC, Saxena A, Chu F, Butler SP, Quinn RJ, Glenn D, et al. Hepatic resection with or without adjuvant iodine-131-lipiodol for hepatocellular carcinoma: a comparative analysis. Int J Clin Oncol. 2011;16:125–32.

    Article  CAS  PubMed  Google Scholar 

  27. Chung AYF, Ooi LLPJ, Machin D, Tan SB, Goh BKP, Wong JS, et al. Adjuvant hepatic intra-arterial Iodine-131-Lipiodol following curative resection of hepatocellular carcinoma: a prospective randomized trial. World J Surg. 2013;37:1356–61.

    Article  CAS  PubMed  Google Scholar 

  28. Okada S, Shimada K, Yamamoto J, Takayama T, Kosuge T, Yamasaki S, et al. Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology. 1994;106:1618–24.

    Article  CAS  PubMed  Google Scholar 

  29. Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology. 1997;25:87–92.

    Article  CAS  PubMed  Google Scholar 

  30. Ercolani G, Grazi GL, Ravaioli M, Del Gaudio M, Gardini A, Cescon M, et al. Liver resection for hepatocellular carcinoma on cirrhosis. Ann Surg. 2003;237:536–43.

    PubMed  PubMed Central  Google Scholar 

  31. Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GAM, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243:229–35.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Wu J-C, Huang Y-H, Chau G-Y, Su C-W, Lai C-R, Lee P-C, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol. 2009;51:890–7.

    Article  PubMed  Google Scholar 

  33. Arii S, Tanaka S, Mitsunori Y, Nakamura N, Kudo A, Noguchi N, et al. Surgical strategies for hepatocellular carcinoma with special reference to anatomical hepatic resection and intraoperative contrast-enhanced ultrasonography. Int Soc Cell. 2010;78(Suppl 1):125–30.

    Google Scholar 

  34. Ahmadzadehfar H, Sabet A, Wilhelm K, Biersack HJ, Risse J. Iodine-131-Lipiodol therapy in hepatic tumours. Methods. 2011;55:246–52.

    Article  CAS  PubMed  Google Scholar 

  35. Zhao W-H, Ma Z-M, Zhou X-R, Feng Y-Z, Fang B-S. Prediction of recurrence and prognosis in patients with hepatocellular carcinoma after resection by use of CLIP score. World J Gastroenterol. 2002;8:237–42.

    PubMed  PubMed Central  Google Scholar 

  36. Gong L, Shi L, Sun J, Yuan W-S, Chen J-F, Liu P, et al. Comparative survival analysis of adjuvant therapy with iodine-131-labeled lipiodol to hepatic resection of primary hepatocellular carcinoma: a meta-analysis. Nucl Med Commun. 2014;35:484–92.

    Article  CAS  PubMed  Google Scholar 

  37. Tabone M, Vigano’ L, Ferrero A, Pellerito R, Carbonatto P, Capussotti L. Prevention of intrahepatic recurrence by adjuvant 131iodine-labeled lipiodol after resection for hepatocellular carcinoma in HCV-related cirrhosis. Eur J Surg Oncol. 2007;33:61–6.

    Article  CAS  PubMed  Google Scholar 

  38. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138:52–64.

    Article  CAS  PubMed  Google Scholar 

  39. Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. Hepatology. 2013;58:2188–97.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors are very indebted to Philip Robinson for his help in English revision.

Authors’ contributions

JO (collection and analysis of data, and writing), FM (collection of data), OG (statistical analysis and analysis of data), MNH, CL-B, LH, OB, TW, CP, PP, PJV, JPV, FB-C, JYS (patients’ care and analysis of data), JD (study concept and design, patients’ care, analysis of data, and writing).

Author information

Authors and Affiliations

  1. Hospices civils de Lyon, Hôpital Edouard Herriot, Fédération des Spécialités Digestives, pavillon L, 69437, Lyon Cedex 03, France

    Jonathan Olesinski, François Mithieux, Olivier Guillaud, Catherine Lombard-Bohas, Luc Henry, Olivier Boillot, Thomas Walter, Christian Partensky, Pierre Paliard, Pierre-Jean Valette & Jérôme Dumortier

  2. Service d’hépato-gastro-entérologie, CHU de Grenoble, Hôpital A. Michallon, La Tronche, France

    Marie-Noëlle Hilleret

  3. Université Claude Bernard Lyon 1, Lyon, France

    Olivier Boillot, Thomas Walter, Christian Partensky, Pierre Paliard, Pierre-Jean Valette & Jean-Yves Scoazec

  4. Service de Médecine nucléaire, CHU de Grenoble, Hôpital A. Michallon, La Tronche, France

    Jean-Philippe Vuillez & Jérôme Dumortier

  5. Université Joseph Fourier, Grenoble, France

    Jean-Philippe Vuillez

  6. Service de Médecine Nucléaire, Hospices civils de Lyon, Hôpital Cardiologique Louis Pradel, Lyon, France

    Françoise Borson-Chazot

  7. Service Central d’Anatomie et Cytologie Pathologiques, Hospices civils de Lyon, Hôpital Edouard Herriot, Lyon, France

    Jean-Yves Scoazec

Authors
  1. Jonathan Olesinski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. François Mithieux
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Olivier Guillaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marie-Noëlle Hilleret
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Catherine Lombard-Bohas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Luc Henry
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Olivier Boillot
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Thomas Walter
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Christian Partensky
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Pierre Paliard
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Pierre-Jean Valette
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jean-Philippe Vuillez
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Françoise Borson-Chazot
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Jean-Yves Scoazec
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Jérôme Dumortier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jérôme Dumortier.

Ethics declarations

Conflict of interest and sources of funding

A part of the patients included in the present analysis was included in a study funded from a grant of the French Programme Hospitalier de Recherche Clinique Régional 2003.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Olesinski, J., Mithieux, F., Guillaud, O. et al. Survival and prognostic factors after adjuvant 131iodine-labeled lipiodol for hepatocellular carcinoma: a retrospective analysis of 106 patients over 20 years. Ann Nucl Med 31, 379–389 (2017). https://doi.org/10.1007/s12149-017-1165-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-017-1165-4

Keywords

Search

Navigation